샘플 요청 목록

 카트 문의
시장보고서
상품코드
1794687

세계의 렘수면행동장애 시장

REM Sleep Behavior Disorders
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 271 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

렘수면행동장애 세계 시장은 2030년까지 16억 달러에 달할 전망

2024년에 12억 달러로 추정되는 렘수면행동장애 세계 시장은 분석 기간인 2024-2030년에 CAGR 5.0%로 성장하여 2030년에는 16억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 클로나제팜은 CAGR 5.4%를 기록하며 분석 기간 종료시에는 9억 6,420만 달러에 달할 것으로 예측됩니다. 멜라토닌 분야의 성장률은 분석 기간 동안 CAGR 3.9%로 추정됩니다.

미국 시장은 3억 2,380만 달러로 추정, 중국은 CAGR 8.0%로 성장할 것으로 예측

미국의 렘수면행동장애 시장은 2024년에 3억 2,380만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2024년부터 2030년 분석 기간 동안 CAGR 8.0%로 성장하여 2030년에는 3억 1,650만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 2.4%와 5.0%로 예측됩니다. 유럽에서는 독일이 CAGR 3.2%로 성장할 것으로 예측됩니다.

세계의 렘수면행동장애 시장 - 주요 동향과 촉진요인 정리

렘수면행동장애를 특징적이고 복잡한 신경학적 상태로 만드는 것은 무엇일까?

렘수면행동장애(RBD)는 렘수면에 수반되는 정상적인 근육 마비의 상실을 특징으로 하는 수면 동반 질환으로, 그 결과 선명하고 종종 폭력적인 꿈을 신체적으로 연기하게 됩니다. 이 질환은 파킨슨병, 다계통위축증, 레비소체형 치매 등 신경퇴행성 질환과의 연관성으로 인해 다른 수면장애와 구분됩니다. 대부분의 경우, RBD 환자들은 이러한 신경질환의 인지 및 운동 증상이 나타나기 훨씬 전에 꿈 실현 행동을 보이기 때문에 RBD는 초기 임상 바이오마커로 자리매김하고 있습니다.

RBD의 전조증상으로서의 가치가 임상적으로 인식되면서 신경과 전문의와 수면 전문의가 환자를 모니터링하고 관리하는 방법이 재구성되고 있습니다. 기존에는 RBD에 대한 인지도가 낮고 정기적인 수면검사가 이루어지지 않아 진단이 제대로 이루어지지 않았으나, 현재는 노인이나 신경변성 위험이 있는 환자들을 대상으로 보다 체계적인 조사가 이루어지고 있습니다. 그 전형적인 증상인 수면 중 잦은 사지 운동, 발성, 때로는 부상은 환자의 안전뿐만 아니라 장기적인 신경학적 모니터링에도 중요한 의미를 갖습니다. 이 때문에 수면의학, 신경학, 정신의학과의 다학제적 협력이 일반화되어 임상적 수면 평가와 장기 모니터링에 대한 수요가 증가하고 있습니다.

어떤 진단 도구와 모니터링 기술이 임상을 변화시키고 있는가?

비디오 모니터링을 통한 수면다원검사(PSG)는 여전히 RBD 진단의 표준이 되고 있습니다. PSG에서는 근육 활동, 호흡 패턴, 신경 기능과 함께 무긴장 렘수면(RSWA)을 직접 관찰할 수 있습니다. 그러나 밤샘 PSG는 비용이 많이 들고 시간이 오래 걸리며, 자원에 제약이 있는 의료 시스템에서는 확장성이 없습니다. 이러한 제한으로 인해 액티그래피, 근전도 및 시청각 구성요소를 사용하여 외래 환경에서 RBD 증상을 선별하는 휴대용 가정용 수면 모니터링 시스템의 개발이 가속화되고 있습니다.

인공지능을 수면 진단에 통합하는 것도 이 분야를 발전시키고 있습니다. AI 기반 플랫폼은 현재 수면 단계를 자동으로 점수화하고, RSWA를 감지하고, 환자의 운동 패턴을 높은 정확도로 분석할 수 있습니다. 이러한 기술은 위험에 처한 집단을 사전에 선별하고 대규모 역학 연구를 촉진하는 데 특히 유용합니다. 바이오마커 연구 또한 빠르게 발전하고 있는 분야입니다. 뇌척수액, 타액 단백질, 말초 피부 생검에서 α-시누클레인 수치에 대한 연구는 RBD를 확인하고 질병의 진행을 예측하는 비침습적 방법의 가능성을 열어주고 있습니다. PET, DaT SPECT 스캔과 같은 기능적 영상 진단 도구도 마찬가지로 파킨슨 증후군과 관련된 뇌 부위의 무증상 변화를 확인하여 조기 진단을 돕고 있습니다.

증상과 병태에 대응하기 위해 치료법은 어떻게 진화하고 있을까?

현재 RBD의 치료는 주로 증상 완화에 초점을 맞추고 있습니다. 벤조디아제핀의 일종인 클로나제팜은 렘수면 중 비정상적인 움직임을 억제하고 수면의 연속성을 개선하기 위해 오랫동안 사용되어 왔습니다. 그러나 인지장애, 주간 졸음 등의 부작용이 우려되어 대체 약물에 대한 검토가 진행되고 있습니다. 특히 고용량 멜라토닌은 우수한 안전성 프로파일과 꿈의 출현을 억제하는 능력으로 인해 주목을 받고 있습니다. 또한, 효과와 안전성의 균형을 맞추기 위해 저용량의 클로나제팜과 멜라토닌을 동시에 투여하는 병용요법에 반응하는 환자도 있습니다.

현재 진행 중인 임상시험에서는 RBD의 신경 퇴행성 기반을 표적으로 하는 새로운 약리학적 중재가 검토되고 있습니다. 시누클레인의 응집을 조절하고 미토콘드리아 기능을 강화하며 신경염증을 억제하는 것을 목표로 하는 임상시험용 약물이 질병 개선과 증상 억제를 목적으로 시험되고 있습니다. 또한, 침실에서 위험물 제거, 침대 레일 설치, 수면 위생 개선과 같은 생활습관 개선은 부상 위험을 줄이는 데 중요한 역할을 합니다. 원격의료 플랫폼은 특히 고령의 거동이 불편한 환자들 사이에서 원격 추적, 순응도 추적, 증상 악화의 조기 발견을 제공하기 위해 채택되고 있습니다.

렘수면행동장애 시장의 성장을 촉진하는 요인은 무엇인가?

렘수면행동장애 시장 성장의 원동력은 신경퇴행성 질환의 유병률 증가, 수면 동반 질환에 대한 인식 개선, 진단 능력의 확대, 임상 연구 자금의 급격한 증가입니다. 전 세계 인구의 고령화에 따라 파킨슨병 및 기타 알파-시누클레인 질환의 발병률이 증가하고 있으며, RBD를 보일 가능성이 있는 사람들의 수가 증가하고 있습니다. 신경퇴행성 질환에 대한 조기 개입의 추진으로 RBD는 센티넬 질환으로 자리매김하고 있으며, 임상적 초점과 환자 지원 활동이 강화되고 있습니다.

의료 인프라, 특히 수면 의료는 수면다원검사, 수면다원검사, 신경과 전문의 진료, 집중치료센터에 대한 접근성을 향상시키며 시장을 뒷받침하고 있습니다. 또한, 공공 및 민간 연구 자금으로 RBD를 예측 바이오마커로 탐색하는 대규모 종단연구가 가능해져 진단 및 치료제 기술 혁신에 박차를 가하고 있습니다. 업계는 접근성 격차를 해소하기 위해 웨어러블 진단 도구와 AI를 탑재한 소프트웨어 솔루션을 적극적으로 개발하고 있습니다. 규제 당국이 RBD 관련 진단 및 치료제의 승인 경로를 촉진하는 데 관심을 보이고 있어, 향후 10년간 시장은 지속적으로 확대될 것으로 전망됩니다.

부문

약물 유형(클로나제팜, 멜라토닌, 기타 약물 유형), 최종사용자(병원 최종사용자, 진료소 최종사용자, 기타 최종사용자)

조사 대상 기업 사례

  • Advanced Brain Monitoring, Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Becton, Dickinson and Company
  • BMC Medical Co., Ltd.
  • Bristol-Myers Squibb Company
  • Cadwell Industries, Inc.
  • Cipla Inc.
  • Compumedics Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Fisher & Paykel Healthcare Limited
  • GlaxoSmithKline plc(GSK)
  • Jazz Pharmaceuticals plc
  • Johnson & Johnson Private Limited
  • Koninklijke Philips N.V.(Philips Healthcare)
  • Merck & Co., Inc.
  • Natus Medical Incorporated
  • Nihon Kohden Corporation
  • Novartis AG
  • Pfizer Inc.
  • Reddy's Laboratories Ltd.
  • ResMed Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계별 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.28

Global REM Sleep Behavior Disorders Market to Reach US$1.6 Billion by 2030

The global market for REM Sleep Behavior Disorders estimated at US$1.2 Billion in the year 2024, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Clonazepam, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$964.2 Million by the end of the analysis period. Growth in the Melatonin segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$323.8 Million While China is Forecast to Grow at 8.0% CAGR

The REM Sleep Behavior Disorders market in the U.S. is estimated at US$323.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$316.5 Million by the year 2030 trailing a CAGR of 8.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global REM Sleep Behavior Disorders Market - Key Trends & Drivers Summarized

What Makes REM Sleep Behavior Disorder a Distinctive and Complex Neurological Condition?

REM Sleep Behavior Disorder (RBD) is a parasomnia characterized by a loss of the normal muscle paralysis that accompanies REM sleep, resulting in individuals physically acting out vivid, and often violent, dreams. This condition stands apart from other sleep disorders due to its association with neurodegenerative diseases such as Parkinson’s disease, multiple system atrophy, and dementia with Lewy bodies. In most cases, patients with RBD exhibit dream enactment behavior long before cognitive or motor symptoms of these neurological conditions manifest, positioning RBD as an early clinical biomarker.

The growing clinical recognition of RBD’s prodromal value is reshaping the way neurologists and sleep specialists monitor and manage patients. Traditionally underdiagnosed due to limited awareness and lack of routine sleep studies, RBD is now being investigated more systematically in aging populations and individuals at risk of neurodegeneration. Its typical manifestation-frequent limb movements, vocalizations, and sometimes injuries during sleep-has significant implications not only for patient safety but also for long-term neurological surveillance. This has resulted in increased demand for clinical sleep assessments and longitudinal monitoring, with interdisciplinary collaboration between sleep medicine, neurology, and psychiatry becoming more commonplace.

Which Diagnostic Tools and Monitoring Technologies Are Transforming Clinical Practices?

Polysomnography (PSG) with video monitoring remains the gold standard for RBD diagnosis. PSG enables direct observation of REM sleep without atonia (RSWA), along with muscle activity, respiratory patterns, and neurological function. However, full-night PSG is expensive, time-consuming, and not scalable in resource-constrained health systems. This limitation has accelerated the development of portable home sleep monitoring systems that use actigraphy, electromyography, and audio-visual components to screen for RBD symptoms in ambulatory settings.

The integration of artificial intelligence into sleep diagnostics is also advancing the field. AI-driven platforms can now automatically score sleep stages, detect RSWA, and analyze patient movement patterns with high accuracy. These technologies are especially valuable in pre-screening at-risk populations and facilitating large-scale epidemiological studies. Biomarker research is another area of rapid progress. Investigations into alpha-synuclein levels in cerebrospinal fluid, salivary proteins, and peripheral skin biopsies are opening doors to non-invasive methods for confirming RBD and forecasting disease progression. Functional imaging tools such as PET and DaT SPECT scans are likewise supporting early diagnosis by identifying subclinical changes in brain regions associated with Parkinsonian syndromes.

How Is the Treatment Landscape Evolving to Address Symptomatology and Underlying Pathologies?

Currently, the treatment of RBD is focused primarily on symptom mitigation. Clonazepam, a benzodiazepine, has long been used to suppress abnormal movements during REM sleep and improve sleep continuity. However, concerns about side effects, including cognitive impairment and daytime drowsiness, have prompted exploration of alternatives. Melatonin, particularly in high doses, has gained prominence for its favorable safety profile and ability to reduce dream enactment. Some patients also respond to combined therapies, where lower doses of clonazepam are administered alongside melatonin to balance efficacy and safety.

Ongoing clinical trials are now exploring novel pharmacological interventions targeting the neurodegenerative underpinnings of RBD. Investigational drugs aimed at modulating synuclein aggregation, enhancing mitochondrial function, or reducing neuroinflammation are being tested for both disease modification and symptomatic control. Additionally, lifestyle adaptations-such as removing hazardous objects from bedrooms, installing bed rails, and improving sleep hygiene-play a critical role in reducing injury risk. Telehealth platforms are also being adopted to offer remote follow-ups, compliance tracking, and early detection of symptom exacerbation, particularly among elderly and immobile patients.

What Factors Are Driving the Growth of the REM Sleep Behavior Disorders Market?

The growth in the REM Sleep Behavior Disorders market is driven by rising neurodegenerative disease prevalence, improved awareness of parasomnias, expanded diagnostic capabilities, and a surge in clinical research funding. As global populations age, the incidence of Parkinson’s disease and other alpha-synucleinopathies is increasing, raising the number of individuals likely to present with RBD. The push for early intervention in neurodegenerative conditions has positioned RBD as a sentinel disorder, resulting in greater clinical focus and patient outreach efforts.

Healthcare infrastructure improvements, particularly in sleep medicine, are supporting the market by increasing access to polysomnography, neurologist consultations, and multidisciplinary care centers. Furthermore, public and private research funding is enabling large-scale longitudinal studies that explore RBD as a predictive biomarker, fueling innovation in diagnostics and therapeutics. Industry players are actively developing wearable diagnostic tools and AI-powered software solutions to fill the accessibility gap. With regulators showing interest in facilitating approval pathways for RBD-related diagnostics and treatments, the market is positioned for sustained expansion over the next decade.

SCOPE OF STUDY:

The report analyzes the REM Sleep Behavior Disorders market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Clonazepam, Melatonin, Other Drug Types); End-Use (Hospitals End-Use, Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Advanced Brain Monitoring, Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Becton, Dickinson and Company
  • BMC Medical Co., Ltd.
  • Bristol-Myers Squibb Company
  • Cadwell Industries, Inc.
  • Cipla Inc.
  • Compumedics Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Fisher & Paykel Healthcare Limited
  • GlaxoSmithKline plc (GSK)
  • Jazz Pharmaceuticals plc
  • Johnson & Johnson Private Limited
  • Koninklijke Philips N.V. (Philips Healthcare)
  • Merck & Co., Inc.
  • Natus Medical Incorporated
  • Nihon Kohden Corporation
  • Novartis AG
  • Pfizer Inc.
  • Reddy's Laboratories Ltd.
  • ResMed Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • REM Sleep Behavior Disorders - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Recognition of Sleep Health as a Medical Priority Expands Clinical Focus
    • Rising Geriatric Population Drives Prevalence of REM Sleep Behavior Disorders
    • Improved Access to Sleep Diagnostics Strengthens Early Detection Rates
    • Integration of Polysomnography and Wearables Accelerates Diagnosis Efficiency
    • Increasing Linkages Between Neurodegenerative Disorders and REM Behavior Issues Spur Research
    • Innovation in Non-Invasive Therapies Promotes Patient Acceptance and Treatment Compliance
    • Pharmaceutical Pipeline Developments Throw the Spotlight on Novel Therapeutic Agents
    • Expansion of Sleep Clinics and Centers Supports Specialist Treatment Options
    • Development of Digital Sleep Monitoring Platforms Enhances Patient Monitoring Accuracy
    • Use of AI in Sleep Pattern Analysis Generates Predictive Insight Opportunities
    • Patient Advocacy and Awareness Campaigns Accelerate Diagnosis and Intervention
    • Regulatory Approvals for Targeted Drugs Stimulate Industry Investment
    • Collaborations Between Neurologists and Sleep Specialists Foster Holistic Care Models
    • Genetic and Biomarker Research Improves Understanding of Underlying Mechanisms
    • Adoption of Telehealth Platforms Enables Broader Reach of Sleep Disorder Therapies
    • Clinical Trials Focused on Parkinson's Disease Patients Expand Data on REM Disruptions
    • Expansion of Reimbursement Coverage Encourages Wider Treatment Uptake
    • Inclusion of Sleep Modules in Wellness Platforms Broadens Consumer Awareness
    • Multimodal Treatment Approaches Drive Innovation in Care Delivery
    • Public Health Emphasis on Sleep Quality Positions REM Disorders as High-Priority Segment
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World REM Sleep Behavior Disorders Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for REM Sleep Behavior Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for REM Sleep Behavior Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Clonazepam by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Clonazepam by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Clonazepam by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Melatonin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Melatonin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Melatonin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for REM Sleep Behavior Disorders by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for REM Sleep Behavior Disorders by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for REM Sleep Behavior Disorders by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for REM Sleep Behavior Disorders by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for REM Sleep Behavior Disorders by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for REM Sleep Behavior Disorders by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for REM Sleep Behavior Disorders by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for REM Sleep Behavior Disorders by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제